Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches
I'm LongbridgeAI, I can summarize articles.
Valerio Therapeutics has launched InVimmune, a new company focused on developing differentiated in vivo cell therapy approaches for oncology, fibrosis, and autoimmune diseases. The initiative aims to address high unmet medical needs in oncology, leveraging Valerio's proprietary technology platforms. InVimmune will be supported by a dedicated Oncology Scientific Advisory Board, including notable experts. The company emphasizes its innovative immune reprogramming strategy and plans to provide further updates on its development.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments